A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness
Dominique Bremond-Gignac,1,2 Riadh Messaoud,3 Sihem Lazreg,4 Claude Speeg-Schatz,5 Didier Renault,6 Frédéric Chiambaretta7,8 On behalf of the Azithromycin Pediatric Study Group 1Ophthalmology Department, Centre St Victor, University Hospital of Amiens, Picardie Jules Verne Un...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6c9487db7a16446fabe99f5e97125d78 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6c9487db7a16446fabe99f5e97125d78 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6c9487db7a16446fabe99f5e97125d782021-12-02T08:41:26ZA 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness1177-5483https://doaj.org/article/6c9487db7a16446fabe99f5e97125d782015-04-01T00:00:00Zhttp://www.dovepress.com/a-3-day-regimen-with-azithromycin-15-eyedrops-for-the-treatment-of-pur-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Dominique Bremond-Gignac,1,2 Riadh Messaoud,3 Sihem Lazreg,4 Claude Speeg-Schatz,5 Didier Renault,6 Frédéric Chiambaretta7,8 On behalf of the Azithromycin Pediatric Study Group 1Ophthalmology Department, Centre St Victor, University Hospital of Amiens, Picardie Jules Verne University, Amiens, France; 2CNRS FR3636, Paris V University, France; 3Ophthalmology Department, Tahar Sfar University Hospital, Mahdia, Tunisia; 4Dar El Beida, Blida, Algeria; 5Ophthalmology Department, University Hospital of Strasbourg, Strasbourg, France; 6Laboratoires THÉA, Clermont-Ferrand, France; 7Ophthalmology Department, University Hospital of Clermont-Ferrand, Gabriel Montpied Hospital, Clermont-Ferrand, France; 8EA 7281 R2D2, Auvergne University, Clermont-Ferrand, France Purpose: To compare the efficacy of azithromycin 1.5% versus tobramycin 0.3% eyedrops on clinical ocular signs and symptoms of bacterial conjunctivitis in children and to assess the parents’ satisfaction regarding the dosing regimen.Patients and methods: An international, multicenter, randomized, investigator-masked, controlled clinical trial conducted in children (1 day to 18 years old) with bulbar conjunctival hyperemia and purulent discharge. Azithromycin 1.5% was administered as 1 drop twice daily for 3 days, and tobramycin 0.3% as 1 drop every 2 hours for 2 days, then 4 times daily for 5 days.Results: A total of 286 patients (mean age: 3.2 years) were enrolled. In children with bacteriologically positive cultures (N=203), azithromycin produced a significantly greater improvement in conjunctival discharge (P<0.01) and a trend (P=0.054) toward improvement in conjunctival hyperemia at day 7 than did tobramycin. Complete resolution of conjunctival discharge was significantly more frequent at day 3 on azithromycin than tobramycin (P=0.005). More parents found azithromycin easier to use (in terms of treatment duration, total number of instillations, instilling drops during the day, and difficulty in performing daily activities) than tobramycin.Conclusion: The azithromycin 1.5% regimen produced a rapid resolution of cardinal signs of purulent bacterial conjunctivitis with a more convenient dosage regimen. Such improved convenience is likely to improve compliance and lessen the burden of illness for patients and carers. Keywords: acceptability, azithromycin, bacterial conjunctivitis, children, compliance, topical antibiotics, QOLBremond-Gignac DMessaoud RLazreg SSpeeg-Schatz CRenault DChiambaretta FDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 725-732 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Bremond-Gignac D Messaoud R Lazreg S Speeg-Schatz C Renault D Chiambaretta F A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness |
| description |
Dominique Bremond-Gignac,1,2 Riadh Messaoud,3 Sihem Lazreg,4 Claude Speeg-Schatz,5 Didier Renault,6 Frédéric Chiambaretta7,8 On behalf of the Azithromycin Pediatric Study Group 1Ophthalmology Department, Centre St Victor, University Hospital of Amiens, Picardie Jules Verne University, Amiens, France; 2CNRS FR3636, Paris V University, France; 3Ophthalmology Department, Tahar Sfar University Hospital, Mahdia, Tunisia; 4Dar El Beida, Blida, Algeria; 5Ophthalmology Department, University Hospital of Strasbourg, Strasbourg, France; 6Laboratoires THÉA, Clermont-Ferrand, France; 7Ophthalmology Department, University Hospital of Clermont-Ferrand, Gabriel Montpied Hospital, Clermont-Ferrand, France; 8EA 7281 R2D2, Auvergne University, Clermont-Ferrand, France Purpose: To compare the efficacy of azithromycin 1.5% versus tobramycin 0.3% eyedrops on clinical ocular signs and symptoms of bacterial conjunctivitis in children and to assess the parents’ satisfaction regarding the dosing regimen.Patients and methods: An international, multicenter, randomized, investigator-masked, controlled clinical trial conducted in children (1 day to 18 years old) with bulbar conjunctival hyperemia and purulent discharge. Azithromycin 1.5% was administered as 1 drop twice daily for 3 days, and tobramycin 0.3% as 1 drop every 2 hours for 2 days, then 4 times daily for 5 days.Results: A total of 286 patients (mean age: 3.2 years) were enrolled. In children with bacteriologically positive cultures (N=203), azithromycin produced a significantly greater improvement in conjunctival discharge (P<0.01) and a trend (P=0.054) toward improvement in conjunctival hyperemia at day 7 than did tobramycin. Complete resolution of conjunctival discharge was significantly more frequent at day 3 on azithromycin than tobramycin (P=0.005). More parents found azithromycin easier to use (in terms of treatment duration, total number of instillations, instilling drops during the day, and difficulty in performing daily activities) than tobramycin.Conclusion: The azithromycin 1.5% regimen produced a rapid resolution of cardinal signs of purulent bacterial conjunctivitis with a more convenient dosage regimen. Such improved convenience is likely to improve compliance and lessen the burden of illness for patients and carers. Keywords: acceptability, azithromycin, bacterial conjunctivitis, children, compliance, topical antibiotics, QOL |
| format |
article |
| author |
Bremond-Gignac D Messaoud R Lazreg S Speeg-Schatz C Renault D Chiambaretta F |
| author_facet |
Bremond-Gignac D Messaoud R Lazreg S Speeg-Schatz C Renault D Chiambaretta F |
| author_sort |
Bremond-Gignac D |
| title |
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness |
| title_short |
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness |
| title_full |
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness |
| title_fullStr |
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness |
| title_full_unstemmed |
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness |
| title_sort |
3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/6c9487db7a16446fabe99f5e97125d78 |
| work_keys_str_mv |
AT bremondgignacd a3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT messaoudr a3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT lazregs a3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT speegschatzc a3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT renaultd a3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT chiambarettaf a3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT bremondgignacd 3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT messaoudr 3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT lazregs 3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT speegschatzc 3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT renaultd 3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness AT chiambarettaf 3dayregimenwithazithromycin15eyedropsforthetreatmentofpurulentbacterialconjunctivitisinchildrenefficacyonclinicalsignsandimpactontheburdenofillness |
| _version_ |
1718398420858699776 |